Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center

Blood (2025) 146 (Supplement 1): 4074.

https://doi.org/10.1182/blood-2025-4074

Published: 2025

Journal Articles

Impact of induction response and co-mutations on transplant outcomes in AML with myelodysplasia-related gene mutations: A multicenter retrospective study

Xing Chen, Ruoxuan Zhang, Liang Huang, Xiaodong Mo, Xiaoxia Hu, Yang Cao

Blood (2025) 146 (Supplement 1): 3394.

https://doi.org/10.1182/blood-2025-3394

Published: 2025

Journal Articles

First-in-human Phase I study of autologous CD5-knockout anti-CD5 CAR-T cells in CD5⁺ hematologic malignancies

Jiali Cheng, Li Zhu, Jia Wu, Yuhan Zeng, Xia Mao, Jue Wang, Liang Huang, Yi Xiao, Xiaoxi Zhou, Wei Mu, Xiaojian Zhu

Blood (2025) 146 (Supplement 1): 5949.

https://doi.org/10.1182/blood-2025-5949

Published: 2025

Journal Articles

Novel risk stratification of ph-like ALL cohort receiving CD19-directed CAR-T therapy

Cai Zihong, Bailin He, Baiwei Luo, Zhixiang Wang, Wenhao Zhong, Xuan Zhou, Qifa Liu, Peng Li, Yong-xian Hu, Jing PAN, Liang Huang, Hongsheng Zhou

Blood (2025) 146 (Supplement 1): 5108.

https://doi.org/10.1182/blood-2025-5108

Published: 2025

Journal Articles

Polatuzumab vedotin retains potent activity against CD79B mutations: Preclinical and clinical efficacy in diffuse large B-cell lymphoma

Zigang Dai, Yixin Yan, Liang Huang

Blood (2025) 146 (Supplement 1): 1923.

https://doi.org/10.1182/blood-2025-1923

Published: 2025

Journal Articles

Robust assessment of early MRD levels could further improve treatment outcomes in low-risk patients of pediatric acute lymphoblastic leukemia: The Report of Taiwan Pediatric Oncology Group (TPOG)-ALL Study

Blood (2025) 146 (Supplement 1): 1550.

https://doi.org/10.1182/blood-2025-1550

Published: 2025

Journal Articles

Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)

Rui Lv, Tingyu Wang, Yuting Yan, Tengteng Yu, Xiong Wenjie, Ying Yu, Qi Wang, Shuaishuai Zhang, Hesong Zou, Shuhui Deng, Yan Xu, Dehui Zou, Liang Huang, Gang An, Lugui Qiu, Shuhua Yi

Blood (2025) 146 (Supplement 1): 5379.

https://doi.org/10.1182/blood-2025-5379

Published: 2025

Journal Articles

Nanobody-based CD19/CD20 bispecific CAR-T achieves durable remissions in r/r NHL patients

Na Kuang, Shuyu Qiang, Lin Wang, Shuhong Li, Liang Huang

Blood (2025) 146 (Supplement 1): 3724.

https://doi.org/10.1182/blood-2025-3724

Published: 2025

Journal Articles

An IL-10-incorporated predictive model for late immune effector cell-associated hematotoxicity following CAR-T therapy in B-cell malignancies

Shujia Zhang, Liang Huang, Hui Luo, Shanwei Ye, Xiaoxi Zhou

Blood (2025) 146 (Supplement 1): 4167.

https://doi.org/10.1182/blood-2025-4167

Published: 2025

Journal Articles

Promising safety and efficacy of equecabtagene autoleucel (eque-cel) followed ASCT in ultra high-risk multiple Myeloma (UHR-MM) patients: primary real world data from a single center

Blood (2025) 146 (Supplement 1): 2299.

https://doi.org/10.1182/blood-2025-2299

Published: 2025

Journal Articles

Prognostic impact of transplant conditioning intensity (TCI) score and minimal identifiable disease (MID) in MDS: A multicenter trophy group study

Ruoxuan Zhang, Yang Cao, Hua Jin, Wei Shi, Xiaoxia Hu, Liang Huang

Blood (2025) 146 (Supplement 1): 4205.

https://doi.org/10.1182/blood-2025-4205

Published: 2025

Journal Articles

Serum free light chain escape before IMWG progression: A predictive marker and a therapeutic opportunity

Blood (2025) 146 (Supplement 1): 4015.

https://doi.org/10.1182/blood-2025-4015

Published: 2025

Journal Articles

Superiority in the Longer Duration of Response and Better Central Nervous System Penetration of CAR-T Cell Therapy over Blinatumomab Infusion for Relapsed/ Refractory B-Cell Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis

Yuhang Cheng, Xueyan Sun, Meijuan Huang, Lei Zhao, Jue Wang, Hanyu Wang, Wanying Liu, Shanwei Ye, Liang Huang, Gaoxiang Wang, Yang Cao

Blood (2024) 144 (Supplement 1): 1447.

https://doi.org/10.1182/blood-2024-207442

Published: 2024

Journal Articles

Type I Interferon Impairs the Function of CAR-T Cells By Disrupting Immune Synapse Assembly

Meijuan Huang, Lei Zhao, Yuhang Cheng, Liang Huang, Jianfeng Zhou, Dengju Li, Jue Wang, Yang Cao

Blood (2024) 144 (Supplement 1): 3407.

https://doi.org/10.1182/blood-2024-197968

Published: 2024

Journal Articles

Targeted-Delivery Strategy of Engineered EV Functionalized By Anti-CD3/CD19 Bi-Specific T-Cell Engager in Treating B-Cell Malignancies

Xiuiu Yang, Shanwei Ye, Qian Xu, Jue Wang, Caroline Markmann, Lingfeng Zhang, Shujia Zhang, Xinyue Deng, Jiali Cheng, Jia Wu, Vijay Bhoj, Zheng Zhang, Liang Huang

Blood (2024) 144 (Supplement 1): 89.

https://doi.org/10.1182/blood-2024-210125

Published: 2024

Journal Articles

The Impacts of Circulating Lymphoblasts and the Day of the First Triple Intrathecal Therapy on the CNS Outcomes of Childhood ALL: The Report of Taiwan Pediatric Oncology Group (TPOG)-ALL-2013

Blood (2024) 144 (Supplement 1): 2804.

https://doi.org/10.1182/blood-2024-200874

Published: 2024

Journal Articles

The Expression of BTG1 in De Novo AML Patients Regulated By Demethylation of Decitabine and Its Evaluation in the Deep Remission of Patients

Shiyuan Zhang, Mengyuan Li, Xiaojian Zhu, Hao Zhou, Bin Xu, Xiwen Tong, Su Shuai, Yi Zhu, Yi Xiao, Liang Huang, Dengju Li, Wei Huang, Jia Wei, Mei Huang, Donghua Zhang

Blood (2024) 144 (Supplement 1): 1401.

https://doi.org/10.1182/blood-2024-205864

Published: 2024

Journal Articles

Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

Blood (2024) 144 (Supplement 1): 4417.

https://doi.org/10.1182/blood-2024-204513

Published: 2024

Journal Articles

Improving CAR-T Cell Function through a Targeted Cytokine Delivery System Utilizing CAR Target-Modified Extracellular Vesicles

Yuanyuan Zhang, Meijuan Huang, Tianjiao Liu, Yuhang Cheng, Dengju Li, Yang Cao, Wei Mu, Liting Chen, Li Zhu, Tongjuan Li, Liang Huang, Jia Wei, Lei Zhao, Jue Wang

Blood (2024) 144 (Supplement 1): 3419.

https://doi.org/10.1182/blood-2024-206731

Published: 2024

Journal Articles

A Phase 2 Clinical Trial of Anti-CD19 CAR-T (pCAR-19B) in Chinese Pediatric and Young Adult with Relapsed/Refractory (R/R) CD19+ B-ALL: The First Pivotal Study in an Asian Population

Blood (2024) 144 (Supplement 1): 4205.

https://doi.org/10.1182/blood-2024-206408

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center

Impact of induction response and co-mutations on transplant outcomes in AML with myelodysplasia-related gene mutations: A multicenter retrospective study

First-in-human Phase I study of autologous CD5-knockout anti-CD5 CAR-T cells in CD5⁺ hematologic malignancies

Novel risk stratification of ph-like ALL cohort receiving CD19-directed CAR-T therapy

Polatuzumab vedotin retains potent activity against CD79B mutations: Preclinical and clinical efficacy in diffuse large B-cell lymphoma

Robust assessment of early MRD levels could further improve treatment outcomes in low-risk patients of pediatric acute lymphoblastic leukemia: The Report of Taiwan Pediatric Oncology Group (TPOG)-ALL Study

Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)

Nanobody-based CD19/CD20 bispecific CAR-T achieves durable remissions in r/r NHL patients

An IL-10-incorporated predictive model for late immune effector cell-associated hematotoxicity following CAR-T therapy in B-cell malignancies

Promising safety and efficacy of equecabtagene autoleucel (eque-cel) followed ASCT in ultra high-risk multiple Myeloma (UHR-MM) patients: primary real world data from a single center

Prognostic impact of transplant conditioning intensity (TCI) score and minimal identifiable disease (MID) in MDS: A multicenter trophy group study

Serum free light chain escape before IMWG progression: A predictive marker and a therapeutic opportunity

Superiority in the Longer Duration of Response and Better Central Nervous System Penetration of CAR-T Cell Therapy over Blinatumomab Infusion for Relapsed/ Refractory B-Cell Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis

Type I Interferon Impairs the Function of CAR-T Cells By Disrupting Immune Synapse Assembly

Targeted-Delivery Strategy of Engineered EV Functionalized By Anti-CD3/CD19 Bi-Specific T-Cell Engager in Treating B-Cell Malignancies

The Impacts of Circulating Lymphoblasts and the Day of the First Triple Intrathecal Therapy on the CNS Outcomes of Childhood ALL: The Report of Taiwan Pediatric Oncology Group (TPOG)-ALL-2013

The Expression of BTG1 in De Novo AML Patients Regulated By Demethylation of Decitabine and Its Evaluation in the Deep Remission of Patients

Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

Improving CAR-T Cell Function through a Targeted Cytokine Delivery System Utilizing CAR Target-Modified Extracellular Vesicles

A Phase 2 Clinical Trial of Anti-CD19 CAR-T (pCAR-19B) in Chinese Pediatric and Young Adult with Relapsed/Refractory (R/R) CD19+ B-ALL: The First Pivotal Study in an Asian Population

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only